Search…

RBC poured cold water on the idea: The likelihood of AstraZeneca (AZN.US) acquiring Bristol-Myers Squibb (BMY.US) is "extremely low," with valuation discrepancies and antitrust concerns posing the biggest hurdles.

04/08/2026

According to the Zhitong Finance APP, investment bank RBC stated that AstraZeneca (AZN.US) is currently unlikely to acquire Bristol-Myers Squibb (BMY.US).

Latest

2 m ago

Deutsche Bank gives China Hongqiao (01378.HK) a "Buy" rating: the inflection point for free cash flow is approaching, and it is expected that over the next five years, cumulative returns through dividends and stock buybacks will exceed the current market value by 60%.

2 m ago

CITIC Construction: Lithium carbonate production capacity is gradually being released, and there will still be no surplus throughout 2027.

3 m ago

Hong Kong Stock Market Movement | Furuya Medical Technology (01696.HK) fell nearly 6%, expected to switch from profit to loss in the first half of the year, facing a severe environment in the North American market with declining sales.

3 m ago

The concept of liquid-cooled servers has seen a surge, and the ice wheel environment is approaching its daily limit.

5 m ago

Hong Kong Stock Market Movements | Gains in Optical Communication Concept Stocks Lead the Pack InP Supply Gap Further Widens Institutions Optimistic About Long-Term Value of Undervalued Hard Technology and Optical Communication

+852 - 60190728

Customer Support

Commercial Services